𧬠Tuhauora Thyroid Cancer ATA 2025 Advisor
Clinical Decision Support Β· 2025 American Thyroid Association DTC Guidelines Β· Ringel & Sosa et al., Thyroid 2025
β οΈ Clinical Decision Support Only. This tool applies the 2025 ATA DTC Guidelines to assist clinician reasoning. It does not replace clinician judgment, MDT review, local protocols, or patient-specific shared decision-making. Always verify recommendations against the source guideline.
π€ Patient Demographics
π¬ Histology & Diagnosis
π Tumour Characteristics (Pathological)
π΅ Nodal Status
π Distant Metastases
π§ͺ Molecular Markers
Molecular markers refine risk stratification. BRAF V600E + TERT promoter co-mutation confers highest risk (Intermediate-High/High). Provide results where available.
πͺ Surgery
π Post-Treatment Biochemistry & Imaging (Dynamic Re-stratification)
Complete this section if surgery (Β±RAI) has been performed to apply response-to-therapy re-stratification (Table 9, ATA 2025).
π Dynamic Risk Re-stratification Figure 6, R51, Table 9, ATA 2025
Enter post-treatment data below to calculate the patient's updated response-to-therapy category and revised risk assessment. This can be used independently or to update the initial analysis.
π Initial Risk Context
π§ͺ Thyroglobulin (Tg) & Anti-Tg Antibodies
For TT+RAI: Excellent = unstimulated Tg <0.2 ng/mL or stimulated Tg <1 ng/mL. Biochemically incomplete = unstimulated >1 or stimulated >10 ng/mL. (Table 9, ATA 2025)
π Neck Ultrasound Findings
π· Additional Imaging (if performed)
π Clinical Context
Enter post-treatment data above and click Compute Re-stratification to see the patient's updated risk category and management plan.
Complete patient data and click Generate Clinical Analysis to view results.
Generate a clinical analysis first to view the 5-year surveillance plan.
Generate a clinical analysis first to view the MDT/EMR summary.
Generate a clinical analysis first to view the patient summary.